Article
Cell Biology
Adriana Carneiro, Paulina Piairo, Alexandra Teixeira, Dylan Ferreira, Sofia Cotton, Carolina Rodrigues, Alexandre Chicharo, Sara Abalde-Cela, Lucio Lara Santos, Luis Lima, Lorena Dieguez
Summary: Gastrointestinal cancers, such as colorectal cancer and gastric cancer, have high morbidity rates worldwide. Epithelial-to-mesenchymal transition (EMT) in cancer promotes the formation of circulating tumor cells (CTCs), which are important for cancer diagnosis and monitoring. However, current CTC isolation approaches are not ideal for capturing EMT or mesenchymal CTCs.
Review
Oncology
Siwei Ju, Cong Chen, Jiahang Zhang, Lin Xu, Xun Zhang, Zhaoqing Li, Yongxia Chen, Jichun Zhou, Feiyang Ji, Linbo Wang
Summary: Circulating tumor cells (CTCs) are cells that shed from a primary tumor and travel through the bloodstream. Studying CTCs can provide in-depth knowledge about lethal tumor diseases. Researchers are working on capturing and detecting CTCs with improved sensitivity and specificity. However, there are still challenges that limit the current use of this diagnostic approach.
BIOMARKER RESEARCH
(2022)
Review
Oncology
Ilaria Cavallari, Francesco Ciccarese, Evgeniya Sharova, Loredana Urso, Vittoria Raimondi, Micol Silic-Benussi, Donna M. D'Agostino, Vincenzo Ciminale
Summary: MicroRNAs of the miR-200 family play crucial roles in regulating gene expression in cancer cells, potentially serving as biomarkers for cancer detection. The mature miR-200 family microRNAs are abundantly expressed in epithelial cells, contributing to maintaining the epithelial phenotype and inhibiting cancer development. These microRNAs exhibit both tumor suppressor and pro-metastatic functions, showing promise as biomarkers for epithelial cancers.
Article
Multidisciplinary Sciences
Jiyoun Seo, Mihir Kumar, Jeremy Mason, Fiona Blackhall, Nicholas Matsumoto, Caroline Dive, James Hicks, Peter Kuhn, Stephanie N. Shishido
Summary: This study aimed to explore the potential of liquid biopsy for stratified treatment of small cell lung cancer (SCLC) based on phenotypic heterogeneity. The study observed phenotypic heterogeneity of circulating rare cells in SCLC and established a classification model to differentiate SCLC patients from non-cancerous donors. Single-cell genomic analysis confirmed the plasticity of cancer cells in these rare cell groups.
SCIENTIFIC REPORTS
(2023)
Article
Medical Laboratory Technology
Lea Sinoquet, William Jacot, Ludovic Gauthier, Stephane Pouderoux, Marie Viala, Laure Cayrefourcq, Xavier Quantin, Catherine Alix-Panabieres
Summary: The presence of PD-L1(+) CTCs is associated with poor prognosis in patients with advanced NSCLC, showing low concordance with PD-L1 expression in tumor tissue, and further studies with larger samples are needed for confirmation.
CLINICAL CHEMISTRY
(2021)
Article
Biophysics
Gang Wang, Yachao Zhang, Shi Tang, Shuning Chen, Fangbo Zou, Hongxiu Yuan, Jin Jiao
Summary: The key factor for glioma invasion and metastasis is the circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition (EMT). This study developed a multivalent aptamer nanoscaffold-based electrochemical cytosensor (MAS-cytosensor) to efficiently detect EMT-CTCs. The MAS-cytosensor can detect EMT-CTCs sensitively and allows for further downstream analysis after release with high viability.
BIOSENSORS & BIOELECTRONICS
(2023)
Review
Oncology
Huikai Zhang, Fanen Yuan, Yangzhi Qi, Baohui Liu, Qianxue Chen
Summary: Liquid biopsy has been applied in various cancers but little progress has been made in validating circulating biomarkers for brain malignancies. Data on circulating tumor cells in glioma are limited, and their application as a biomarker has just begun.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jiazhang Wei, Weiming Deng, Jingjin Weng, Min Li, Guiping Lan, Xiang Li, Linsong Ye, Yongli Wang, Fei Liu, Huashuang Ou, Yunzhong Wei, Wenlin Huang, Sifang Xie, Guohu Dong, Shenhong Qu
Summary: CTC classification allows for a better understanding of cellular phenotypic changes responsible for locoregional invasion and distant metastasis in nasopharyngeal carcinoma (NPC), and predicts clinical outcomes in patients with progressive NPC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shih-Hong Li, Min-Hsien Wu, Hung-Ming Wang, Ping-Chih Hsu, Yueh-Fu Fang, Chih-Liang Wang, Hui-Chun Chu, Hung-Chih Lin, Li-Yu Lee, Ching-Yang Wu, Cheng-Ta Yang, Jen-Shi Chen, Jason Chia-Hsun Hsieh
Summary: This study developed a hybrid platform using a negative and positive selection strategy to capture circulating tumor cells (CTCs) and detect EGFR mutations in patients with metastatic lung adenocarcinoma. The results showed that CTCs could serve as a reliable source of lung cancer tumor DNA for detecting EGFR mutations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Ophthalmology
Salvatore Grisanti, Friederike Schindler, Hartmut Merz, Vinodh Kakkassery, Svenja Rebecca Sonntag, Ayseguel Tura
Summary: The purpose of this study was to determine the presence of circulating tumor cells (CTCs) in patients with indeterminate small choroidal melanocytic lesions (SCMLs). Blood samples were analyzed for CTCs and tissue biopsy was performed in CTC-positive patients. The study found that the presence of CTCs was associated with certain clinical characteristics and could be used as a potential tool for screening SCMLs for malignancy.
Article
Biology
Jasmina Kuvendjiska, Felix Mueller, Peter Bronsert, Sylvia Timme-Bronsert, Stefan Fichtner-Feigl, Birte Kulemann
Summary: Intraductal papillary mucinous neoplasm (IPMN) is a common precursor lesion of pancreatic cancer (PDAC), and its early diagnosis and treatment are crucial. The clinical management guidelines for IPMN lack satisfactory sensitivity and specificity, calling for further markers. This study isolated circulating epithelial cells (CECs) from IPMN patients, evaluated their characteristics, and compared KRAS mutations in CECs and IPMN tissue, providing additional research possibilities for understanding IPMN biology.
Article
Biochemistry & Molecular Biology
Jacqueline Aparecida Torres, Angelo Borsarelli Carvalho Brito, Virgilio Souza e Silva, Iara Monique Messias, Alexcia Camila Braun, Anna Paula Carreta Ruano, Marcilei E. C. Buim, Dirce Maria Carraro, Ludmilla Thome Domingos Chinen
Summary: Circulating tumor cells (CTCs) and/or circulating tumor microemboli (CTM) from non-small cell lung cancer (NSCLC) patients could serve as a non-invasive tool for prognosis, acting as liquid biopsy. This study found that CTCs/CTMs from NSCLC patients expressed immune evasion markers TGF beta RI/CD47, and the presence of CTMs CD47+ was associated with poor progression-free survival (PFS).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Qiang Zhao, Bingbing Li, Qi Gao, Yang Luo, Liang Ming
Summary: This meta-analysis investigated the prognostic role of EMT-CTCs in patients with breast cancer, revealing that EMT-CTCs were associated with poorer survival outcomes in breast cancer patients. Subgroup analysis showed the association of EMT-CTCs with various factors such as cancer stage, identification method, and sampling volume.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yujin Pan, Deyu Li, Jiuhui Yang, Ning Wang, Erwei Xiao, Lianyuan Tao, Xiangming Ding, Peichun Sun, Dongxiao Li
Summary: This study demonstrates the preferability of portal venous for CTC testing and the association of high PoV M-CTC count with increased risk of metastasis and shorter survival time in resectable PDAC patients. PoV CTC phenotype detection shows potential as a reliable and accurate tool for identifying high-risk PDAC patients for better management strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Jiaxin Zhang, Jie Peng, Deqin Kong, Xiang Wang, Zhao Wang, Jiangzheng Liu, Weihua Yu, Hao Wu, Zi Long, Wei Zhang, Rui Liu, Chunxu Hai
Summary: The NAD+-dependent protein-modifying enzyme SIRT1 plays a crucial role in regulating gene expression, DNA damage repair, cell metabolism, and mitochondrial functions, influencing epithelial-to-mesenchymal transition in lung cancer cells by modulating mitochondrial status.
Article
Oncology
Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Tachihara, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma, Naoko Miura, Kazumi Nishino, Satoshi Hara, Shunsuke Teraoka, Satoshi Morita, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Summary: This study aimed to compare the efficacy and safety of osimertinib plus bevacizumab with osimertinib alone in patients with lung adenocarcinoma with EGFR T790M mutation. The combination therapy showed a better overall response rate but did not prolong progression-free survival compared to osimertinib monotherapy.
Article
Oncology
Hiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, Daichi Fujimoto, Akito Hata, Nobuyuki Katakami, Keisuke Tomii, Eriko Murakami, Takeya Sugimoto, Toshio Shimokawa, Yasuhiro Koh, Nobuyuki Yamamoto
Summary: The study results indicate that the combination of osimertinib plus ramucirumab is safe and effective in patients with EGFR-mutated lung adenocarcinoma, with potential for further investigation into its efficacy.
ANTICANCER RESEARCH
(2021)
Article
Oncology
Kentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, Yoshihiro Hattori, Kazumi Nishino, Haruki Kobayashi, Yuko Oya, Toshihide Yokoyama, Takashi Seto, Koichi Azuma, Tomoya Fukui, Toshiyuki Kozuki, Atsushi Nakamura, Kentaro Tanaka, Katsuya Hirano, Takashi Yokoi, Haruko Daga, Shinya Sakata, Daichi Fujimoto, Masahide Mori, Ken Maeno, Takuya Aoki, Atsuhisa Tamura, Satoru Miura, Satoshi Watanabe, Hiroaki Akamatsu, Osamu Hataji, Kensuke Suzuki, Shigeto Hontsu, Koji Azuma, Akihiro Bessho, Akihito Kubo, Motoyasu Okuno, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Summary: The study revealed that in the sequential therapy of ALK-rearranged non-small cell lung cancer patients with CRZ and ALEC, the combined time-to-treatment failure in the CRZ group was significantly longer than the ALEC group, but there was no significant difference in overall survival between the two groups.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Alberto Servetto, Rahul Kollipara, Luigi Formisano, Chang-Ching Lin, Kyung-Min Lee, Dhivya R. Sudhan, Paula I. Gonzalez-Ericsson, Sumanta Chatterjee, Angel Guerrero-Zotano, Saurabh Mendiratta, Hiroaki Akamatsu, Nicholas James, Roberto Bianco, Ariella B. Hanker, Ralf Kittler, Carlos L. Arteaga
Summary: FGFR1 overexpression in the nucleus of breast cancer cells is associated with endocrine resistance in ER+ breast cancer. Nuclear FGFR1 influences gene transcription and promotes resistance to estrogen suppression and fulvestrant. Treatment with FGFR tyrosine kinase inhibitors does not affect nuclear FGFR1 activity, supporting the development of strategies to inhibit nuclear FGFR1 in ER+/FGFR1 overexpressing breast cancer.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Ariella B. Hanker, Benjamin P. Brown, Jens Meiler, Arnaldo Marin, Harikrishna S. Jayanthan, Dan Ye, Chang-Ching Lin, Hiroaki Akamatsu, Kyung-Min Lee, Sumanta Chatterjee, Dhivya R. Sudhan, Alberto Servetto, Monica Red Brewer, James P. Koch, Jonathan H. Sheehan, Jie He, Alshad S. Lalani, Carlos L. Arteaga
Summary: The study found that the frequent HER3(E928G) kinase domain mutation increases the affinity of HER2/HER3 and reduces the binding of HER2 to its inhibitor neratinib. Co-expression of mutant HER2/HER3 enhances HER2/HER3 co-immunoprecipitation and ligand-independent activation of HER2/HER3 and PI3K/AKT, leading to increased growth, invasiveness, and resistance to HER2-targeted therapies, which can be reversed by combined treatment with PI3K alpha inhibitors.
Article
Oncology
Yuhei Harutani, Yuichi Ozawa, Eriko Murakami, Koichi Sato, Jun Oyanagi, Hiroaki Akamatsu, Takanori Yoshikawa, Ryota Shibaki, Takeya Sugimoto, Katsuyuki Furuta, Shunsuke Teraoka, Nahomi Tokudome, Atsushi Hayata, Hiroki Ueda, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto
Summary: This study found that serum levels of CRP and follistatin before initiation of PD-1/L1 inhibitors were predictive for overall survival in patients without durable clinical benefit, suggesting that the immune status before treatment initiation may play a role in long-term survival outcomes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Toshiaki Takahashi, Kazuko Sakai, Hirotsugu Kenmotsu, Kiyotaka Yoh, Haruko Daga, Tatsuo Ohira, Tsuyoshi Ueno, Tadashi Aoki, Hidetoshi Hayashi, Koji Yamazaki, Yukio Hosomi, Toyofumi F. Chen-Yoshikawa, Norihito Okumura, Yuichi Takiguchi, Akimasa Sekine, Tomohiro Haruki, Hiromasa Yamamoto, Yuki Sato, Hiroaki Akamatsu, Takashi Seto, Sho Saeki, Kenji Sugio, Makoto Nishio, Hidetoshi Inokawa, Nobuyuki Yamamoto, Kazuto Nishio, Masahiro Tsuboi
Summary: This study analyzed the mutation status of tumor tissue DNA from resected stage II-III non-squamous non-small-cell lung cancer patients, revealing a significant association between EGFR mutation and poor prognosis in female patients. The study highlights the importance of mandatory molecular diagnosis and treatment with third-generation tyrosine kinase inhibitors instead of platinum-based chemotherapy for these patients.
Article
Oncology
Hiroaki Akamatsu, Haruyasu Murakami, Hideyuki Harada, Junichi Shimizu, Hidetoshi Hayashi, Haruko Daga, Yoshikazu Hasegawa, Young Hak Kim, Terufumi Kato, Shoji Tokunaga, Yasumasa Nishimura, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Summary: This study aimed to evaluate the efficacy and tolerability of gefitinib plus concurrent thoracic radiotherapy in patients with LA-NSCLC harboring EGFR mutation. The results showed that the combination therapy had good efficacy in these patients, with a median progression-free survival of 18.6 months and a median overall survival of 61.1 months.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Yoshitaka Kawa, Toshihide Yokoyama, Motohiro Tamiya, Ryota Hiraoka, Naoki Shingu, Hideki Ikeda, Akihiro Tamiya, Masaki Kanazu, Eisaku Miyauchi, Satoru Miura, Masaaki Yanai, Makiko Yomota, Ryotaro Morinaga, Takashi Yokoi, Akito Hata, Hidekazu Suzuki, Hirotaka Matsumoto, Shinya Sakata, Naoki Furuya, Yuhei Harutani, Ichiro Nakachi, Ayumu Otsuki, Shinya Uematsu, Satoshi Hara, Keiki Yokoo, Takeya Sugimoto, Nobuyuki Yamamoto
Summary: This study aimed to determine the incidence and clinical course of histologic transformation (HT) in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. The study found that approximately 3% of EGFR-mutated patients developed HT after acquiring resistance to EGFR-tyrosine kinase inhibitors (TKIs). There was no significant difference in survival between patients with transformation to high-grade neuroendocrine carcinoma and those with transformation to another subtype of non-small cell lung cancer. Cytotoxic agents were likely to be effective in patients with HT, while the effectiveness of immune checkpoint inhibitors was limited.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Ryota Shibaki, Yuichi Ozawa, Susumu Noguchi, Yusuke Murakami, Eri Takase, Yuichiro Azuma, Masaru Maebeya, Takeya Sugimoto, Atsushi Hayata, Takahiro Hayakawa, Shinya Tamaki, Masanori Nakanishi, Shunsuke Teraoka, Hiroaki Akamatsu
Summary: This study found that the presence of pre-existing interstitial lung abnormal shadow increased the risk of lung injury in patients with EGFR-mutated non-small cell lung cancer treated with osimertinib, but did not clearly affect the severity of lung injury.
Article
Oncology
Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Summary: This study aimed to explore the efficacy of retreatment with immune checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer (NSCLC) who responded to prior ICI and had adequate ICI-free interval. The results showed that retreatment with nivolumab had limited efficacy in patients who initially responded to prior ICI and had ICI-free interval.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Arnaldo Marin, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker
Summary: This study reveals the driver function of acquired HER2 mutations in resistance to HER2 tyrosine kinase inhibitors, and provides a potential treatment strategy to overcome this resistance.
Article
Nutrition & Dietetics
Takashi Ogasawara, Yasuhisa Tajima, Naoto Nakamura, Hiroki Kanasaki, Wataru Matsuyama, Mitsuru Niwa, Yuichi Ozawa, Masayuki Sugiura, Masahito Ogiku, Jun Sato
Summary: This study aimed to evaluate the efficacy of 1-hydroxy-vitamin D in COVID-19 patients. The results showed that patients treated with 1-hydroxy-vitamin D had a significantly lower proportion of needing respiratory support and in-hospital mortality compared to the control group.
CLINICAL NUTRITION
(2023)
Article
Medicine, General & Internal
Katsuyuki Furuta, Hiroaki Akamatsu, Ryuichi Sada, Kyohei Miyamoto, Shunsuke Teraoka, Atsushi Hayata, Yuichi Ozawa, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto
Summary: The SIRS score was found to be more sensitive in predicting bacteremia compared to the qSOFA score. Multivariable analysis revealed that body temperature and blood pressure were significantly associated with bacteremia.
ACUTE MEDICINE & SURGERY
(2021)
Article
Oncology
Ryota Shibaki, Hiroaki Akamatsu, Terufumi Kato, Kazumi Nishino, Morihito Okada, Tetsuya Mitsudomi, Kazushige Wakuda, Kenichi Yoshimura, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Summary: This study introduces a phase II trial of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected NSCLC with EGFR mutation to evaluate the efficacy of this combination treatment. The primary endpoint is to assess the DFS rate after four cycles of treatment.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)